The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to an EU-based OTC drug manufacturer (Czech Republic) after reviewing documents submitted after a request for records and other information. Key findings include missing incoming material identity testing, no stability program despite labeled expiry dates, inadequate process validation, insufficient method validation and microbiological control, and incomplete laboratory documentation.
